Iovance Just Printed a Record $99 Million Quarter.
Iovance (IOVA) just put up the quarter the long-suffering biotech crowd needed to see.
Record product revenue near $99.3 million. Up about 66% from a year ago and 39% from the first quarter. Gross margin hit an all-time high around 56%. The stock jumped hard as traders finally got a commercial print that looked like a business, not a perpetual clinical teaser.
U.S. Amtagvi revenue was about $91 million. That crushed the company's own second-quarter Amtagvi guide of roughly $79 million to $81 million. Proleukin added about $9 million. Demand, not accounting noise, did the heavy lift.
The Guidance Tell
Management said it is reviewing the full-year 2026 revenue range of $350 million to $370 million and will update in the third quarter. When a company beats its own quarterly band this badly and immediately flags a guidance review, the market hears one word: raise.
CEO language on the print leaned into manufacturing efficiency, pipeline expansion in other solid tumors, and a path toward profitability. You can discount the pep talk. You cannot ignore a 56% margin on a cell-therapy product that used to look like a money pit.
Why the Stock Was So Explosive
IOVA had been a range-bound frustration trade for a long stretch. A record quarter plus a guidance review is the kind of combo that forces short covering and momentum capital into the same door at once. Shares that were stuck in the mid-$4s tore into the mid-$6s on the session. That is not a polite re-rating. That is a squeeze on top of a fundamental beat.
The risk from here is obvious. One hot quarter does not finish the commercialization story. Infusion center build-out, durability of demand, and cash burn still matter. But the debate just moved from "does anyone want this therapy?" to "how fast can they scale it?"
Bottom Line
Bottom Line: Iovance finally showed commercial heat with a $99 million quarter and a guidance review hanging over the back half. Watch the Q3 update. That is where the raise either becomes real or the squeeze fades.
Money Morning is not a registered investment advisor. This article is for informational purposes only and should not be construed as investment advice. Past performance is not indicative of future results. We may receive compensation for promoting third-party products and services. Always do your own due diligence before investing.